Sagimet Biosciences Stock (NASDAQ:SGMT)
Previous Close
$3.40
52W Range
$2.13 - $20.71
50D Avg
$3.05
200D Avg
$4.94
Market Cap
$126.38M
Avg Vol (3M)
$1.09M
Beta
-
Div Yield
-
SGMT Company Profile
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.